SCHEMBL22326226

SCHEMBL22326226

O=C1CCC(n2nnc3ccc(N4CCC(C(=O)O)CC4)cc3c2=O)C(=O)N1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 12/20 0.47
PDE3B Q13370 1/20 0.43
PDE3A Q14432 1/20 0.43
DDB1 Q16531 8/20 0.37
HPGDS O60760 2/20 0.37
IKZF3 Q9UKT9 3/20 0.36
PDK2 Q15119 1/20 0.36
NOTUM Q6P988 1/20 0.35
KDM4E B2RXH2 2/20 0.34
HSD17B10 Q99714 2/20 0.34
USP2 O75604 1/20 0.34
HPGD P15428 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
AKR1C3 P42330 1/20 0.34
IP6K1 Q92551 1/20 0.34
AURKA O14965 1/20 0.34
AURKB Q96GD4 1/20 0.34
GAA P10253 1/20 0.34
TSHR P16473 1/20 0.34
CASP1 P29466 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27208328 0.92 CRBN (0.53) CRBNPDE3BPDE3ADDB1HPGDS
SCHEMBL22326268 0.91 CRBN (0.47) CRBNDDB1IKZF3TSHR
SCHEMBL30767223 0.87 CRBN (0.51) CRBNPDE3BPDE3ADDB1IKZF3
SCHEMBL27012609 0.86 CRBN (0.49) CRBNDDB1IKZF3TSHR
SCHEMBL30905875 0.82 CRBN (0.41) CRBNPDE3BPDE3ADDB1HPGDS
SCHEMBL27208337 0.79 CRBN (0.50) CRBNPDE3BPDE3ADDB1HPGDS
SCHEMBL30767222 0.79 CRBN (0.57) CRBNPDE3BPDE3ADDB1IKZF3
SCHEMBL27208329 0.79 CRBN (0.41) CRBNDDB1HPGDSIKZF3NOTUM
SCHEMBL21751118 0.78 CRBN (0.55) CRBNDDB1IKZF3TSHR
SCHEMBL24233170 0.77 CRBN (0.57) CRBNDDB1IKZF3TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018123-A1 COMPOUND FOR INHIBITING OR DISINTEGRATING ANDROGEN RECEPTOR, AND PHARMACEUTICAL USE THEREOF KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2024-01-18 US disclosed
US-20240018123-A1 COMPOUND FOR INHIBITING OR DISINTEGRATING ANDROGEN RECEPTOR, AND PHARMACEUTICAL USE THEREOF KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2024-01-18 US disclosed
US-20220105188-A1 TARGET PROTEIN EED DEGRADATION-INDUCING DEGRADUCER, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DISEASES RELATED TO EED, EZH2, OR PRC2, COMPRISING SAME AS ACTIVE INGREDIENT KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2022-04-07 US disclosed
WO-2022025640-A1 COMPOUND FOR INHIBITING OR DISINTEGRATING ANDROGEN RECEPTOR, AND PHARMACEUTICAL USE THEREOF 한국화학연구원 2022-02-03 WO disclosed
WO-2020162725-A1 TARGET PROTEIN EED DEGRADATION-INDUCING DEGRADUCER, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DISEASES RELATED TO EED, EZH2, OR PRC2, COMPRISING SAME AS ACTIVE INGREDIENT 한국화학연구원 2020-08-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220105188-A1 TARGET PROTEIN EED DEGRADATION-INDUCING DEGRADUCER, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DISEASES RELATED TO EED, EZH2, OR PRC2, COMPRISING SAME AS ACTIVE INGREDIENT EED, VHL, CUL1 CRBN 4/4885PDE3B 4684/4885PDE3A 4653/4885
US-20240018123-A1 COMPOUND FOR INHIBITING OR DISINTEGRATING ANDROGEN RECEPTOR, AND PHARMACEUTICAL USE THEREOF AR, NR5A1, SHBG CRBN 3597/4885PDE3B 434/4885PDE3A 336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.